It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Identify the Dividend Aristocrats ETF with the lowest fees and understand how fee selection affects long-term performance.
27,609 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
This article dives into amerisafe (amsf) 2025 earnings expectations, outlining key drivers, potential pitfalls, and a...
As 2026 unfolds, REITs offer liquidity and steady income in a rate-sensitive environment. This report highlights the ...
Strategy, led by Michael Saylor, plans to fund STRC dividends by selling Bitcoin, with a long-term goal to buy more B...
As investors eye Regal Rexnord’s Q1 2026 earnings, the focus turns to demand momentum, margin discipline, and capital...
Costco posted solid June numbers, with a 10.6% rise in sales and a strong e-commerce lift. Yet the stock declined, si...
Investors are flocking to energy’s hottest trade: high-yielding integrateds and midstream giants. Fresh cash-flow dat...
Investors are weighing whether UTES's AI-driven utility tilt justifies a roughly 0.50% fee as 2026 market conditions ...
As June 2026 markets churn, traders are weighing ETHT, a 2x Ether futures ETF, against ETHA, a spot Ether trust, amid...
As technology stocks dominate the market, smart money fleeing tech may seek ballast in Johnson & Johnson. This articl...
Global markets offer growth opportunities beyond the U.S. Learn why international diversification matters, how to sta...
Two popular India ETFs offer distinct bets on growth and profitability. This analysis breaks down structure, performa...